podophyllotoxin has been researched along with Hospital-Acquired Condition in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kolygin, BA; Kuleva, SA | 1 |
| Albain, KS; Le Beau, MM; Schumacher, H; Ullirsch, R | 1 |
2 review(s) available for podophyllotoxin and Hospital-Acquired Condition
| Article | Year |
|---|---|
[Long-term consequences of anticancer therapy in children].
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Child; Humans; Iatrogenic Disease; Metals, Heavy; Neoplasms; Podophyllotoxin; Radiotherapy Dosage; Radiotherapy, Adjuvant; Surgical Procedures, Operative; Time Factors | 2012 |
Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Humans; Iatrogenic Disease; Leukemia, Monocytic, Acute; Mastectomy, Radical; Middle Aged; Podophyllotoxin; Radiotherapy; Tamoxifen; Topoisomerase II Inhibitors; Translocation, Genetic | 1990 |